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Association between Anxiety Disorders and Heart Rate Variability in The
Netherlands Study of Depression and Anxiety (NESDA)
CARMILLA M. M. LICHT, MSC, ECO J. C. DE GEUS, PHD, RICHARD VAN DYCK, MD, PHD,
AND BRENDA W. J. H. PENNINX, PHD
Objective: To determine whether patients with different types of anxiety disorder (panic disorder, social phobia, generalized
anxiety disorder) have higher heart rate and lower heart rate variability compared with healthy controls in a sample that was
sufficiently powered to examine the confounding effects of lifestyle and antidepressants. Methods: The standard deviation of the
normal-to-normal intervals (SDNN), heart rate (HR), and respiratory sinus arrhythmia (RSA) were measured in 2059 subjects
(mean age  41.7 years, 66.8% female) participating in The Netherlands Study of Depression and Anxiety (NESDA). Based on
the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV) and Composite International Diagnostic
Interview (CIDI), NESDA participants were classified as healthy controls (n  616), subjects with an anxiety diagnosis earlier in
life (n  420), and subjects with current anxiety diagnosis (n  1059). Results: Current anxious subjects had a significantly lower
SDNN and RSA compared with controls. RSA was also significantly lower in remitted anxious subjects compared with controls.
These associations were similar across the three different types of anxiety disorders. Adjustment for lifestyle had little impact.
However, additional adjustment for antidepressant use reduced all significant associations between anxiety and HRV to nonsig-
nificant. Anxious subjects who used a tricyclic antidepressant, a selective serotonin reuptake inhibitor, or another antidepressant
showed significantly lower mean SDNN and RSA compared with controls (effect sizes  0.20–0.80 for SDNN and 0.42–0.79 for
RSA). Nonmedicated anxious subjects did not differ from controls in mean SDNN and RSA. Conclusion: This study shows that
anxiety disorders are associated with significantly lower HR variability, but the association seems to be driven by the effects of
antidepressants. Key words: anxiety disorder, SDNN, RSA, cardiac vagal control, heart rate, antidepressants.
ANOVA analysis of variance; ANS autonomic nervous system;
ATC  anatomical therapeutic chemical; BAI  Beck Anxiety
Inventory; BMI  body mass index; CIDI  Composite Interna-
tional Diagnostic Interview; CVD  cardiovascular disease; dZ 
changes in thorax impedance; ECG  electrocardiogram; GAD 
generalized anxiety disorder; HR  heart rate; HRV  heart rate
variability; IBI  inter-beat-interval; MDD  major depressive
disorder; MET  multiple of one’s resting metabolic rate times
minutes of physical activity; NESDA  The Netherlands Study of
Depression and Anxiety; PD  panic disorder; pv  peak-valley;
PNS  parasympathetic nervous system; RR  respiratory rate;
RSA  respiratory sinus arrhythmia; SDNN  standard deviation of
the normal-to-normal interval; SNS  sympathetic nervous system;
SP  social phobia; VU-AMS  Vrije Universiteit Ambulatory
Monitoring System; SSRI  selective serotonin reuptake inhibitor;
TCA  tricyclic antidepressant.
INTRODUCTION
A nxiety disorders have been associated with an increasedrisk of cardiovascular morbidity and mortality (1–10).
One of the hypothesized causes for this association is a dys-
regulation of the autonomic control of the heart because
autonomic nervous system (ANS) activity is associated with
cardiovascular disease (CVD) and mortality (11–15) as well
as anxiety disorders. Episodic acute “state” anxiety is charac-
terized by an increase in heart rate (HR) paired to a decrease
in total HR variability (HRV) and respiratory sinus arrhythmia
(RSA) (16–18). The latter is often seen as the best available
proxy for cardiac vagal control (19,20). Lower total HRV and
cardiac vagal control are also found in subjects reporting
chronic levels of anxiety, as assessed by “trait anxiety” inven-
tories (21,22) and in patients with a clinical anxiety disorder
(23–27). A recent review by Friedman (22) suggested that
RSA is lowered most strongly in patients with panic disorder
(PD), when compared with social phobia and generalized
anxiety disorder. Friedman’s review also detected substantial
heterogeneity in the outcome across studies.
A potential limitation of the studies in clinical samples so
far is that they were relatively small and, as a consequence,
could not take into account potential confounders of the rela-
tionship between anxiety and HRV. Specifically, lifestyle
factors and the use of psychoactive medication have not been
taken into account in most of the studies to date. With regard
to the latter, we recently showed that antidepressants had a
major lowering impact on standard deviation of the normal-
to-normal interval (SDNN) and RSA in depressed patients
(28). The present study examines HR, SDNN, and RSA in
subjects with a current or remitted anxiety diagnosis and
healthy controls. The study was sufficiently powered to ex-
amine the extent to which a potential association between
anxiety disorder and HR and HRV is confounded by a number
of lifestyle factors and the use of antidepressants. We also
examined whether differences in HR, SDNN, and RSA were
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consistent across different anxiety disorders (PD, social phobia,
and generalized anxiety disorder) and whether these differences
were larger for anxiety patients with a current diagnosis com-
pared with those with a remitted diagnosis.
METHODS
Subjects
Subjects participating in the present study came from The Netherlands
Study of Depression and Anxiety (NESDA), an ongoing longitudinal cohort
study conducted among 2981 adult subjects (age  18–65 years) to examine
the long-term course of depression and anxiety disorders. The rationale,
methods, and recruitment strategy have been described elsewhere (29). The
NESDA sample consists of 652 persons without depression or anxiety disor-
ders and 2329 with a (remitted or current) diagnosis of depressive or anxiety
disorder. To represent various settings and stages of psychopathology, de-
pressed or anxious subjects were recruited at three different locations in The
Netherlands in different settings: community, primary care, and mental
healthcare organizations. Community-based subjects had previously been
identified in a population-based study, primary care subjects were identified
through a three-stage screening procedure (involving the K10 (30) and the
short-form Composite International Diagnostic Interview (CIDI) psychiatric
interview by phone) conducted among patients of 65 General Practitioners;
and mental healthcare patients were recruited when newly enrolled at one of
the 17 participating mental health organization locations.
NESDA subjects were assessed between September 2004 and February
2007 during a 4-hour visit to one of the seven field center locations. During
this visit, the presence of anxiety disorders was ascertained using the lifetime
version of the CIDI psychiatric interview (World Health Organization (WHO)
version 2.1). The CIDI establishes diagnoses according to the Diagnostic and
Statistical Manual of Mental Disorders, 4th Edition (DSM-IV) criteria (31)
and has shown high interrater and test-retest reliability and high validity for
anxiety disorders (32). In addition, the severity of anxiety was measured among
all subjects using the Beck Anxiety Inventory (BAI) (33).
To test whether HR, SDNN, and RSA differed across persons with and
without an anxiety disorder, three clearly distinct anxiety groups were created
for the present study. The first group consisted of 616 control subjects with no
history of any anxiety disorders, depression, or other psychiatric disorders.
The second group consisted of 420 persons with an anxiety disorder-diagnosis
(as defined by the CIDI) earlier in life but not in the past 6 months. This group
was referred to as the remitted anxiety group. The third group—referred to as
the current anxiety group—consisted of 1159 persons with a CIDI-confirmed
anxiety disorder in the past 6 months (84% had experienced an anxious
episode in the past month). The remaining 786 NESDA subjects were ex-
cluded from the analyses: 688 patients had a depressive disorder in absence of
an anxiety disorder; 98 subjects had missing physiological data due to equipment
failure during assessment or poor electrocardiogram (ECG) quality.
For additional analysis on anxiety subtype, the 1479 anxious subjects
(remitted  current) were further classified based on the CIDI data, in three
variables assessing the presence or absence of remitted or current PD, remit-
ted or current social phobia (SP), and remitted or current generalized anxiety
disorder (GAD).
Measurements
The clinic visit consisted of a blood draw, a medical examination, supine
rest with blood pressure recordings, psychiatric interviews, a cognitive com-
puter task, saliva collection, and administration of several written question-
naires concerning mood state, lifestyle, medical history, and actual medication
use. Extensive information about psychological, biological, physical, and
demographic determinants was collected. The study protocol was approved
centrally by the Ethical Review Board of the VU University Medical Center
and subsequently by local review boards of each participating center. All
subjects signed an informed consent at baseline assessment.
Physiological Measurement
HR and SDNN were assessed using a three-lead ECG signal that was
measured by the VU-AMS. The VU-AMS is a light-weight ambulatory device
that records the ECG and changes in thorax impedance (dZ) from six elec-
trodes placed on the chest and back of the subjects (34,35). The respiration
signal is obtained from the filtered (0.1–0.4 Hz) dZ signal. An automatic
scoring algorithm detects the beginning and end of inspiration and expiration
and computes the respiratory rate (RR) from these values. RSA was assessed
by peak-valley estimation (pvRSA) using the combined ECG and dZ signals.
Per breath, estimates of pvRSA were obtained by subtracting the shortest
inter-beat-interval (IBI) during HR acceleration in the inspirational phase
(which was made to include 750 milliseconds from the following expiration
to account for phase shifts) from the longest IBI during deceleration in the
expirational phase (including 750 milliseconds from the following expiratory
pause/inspirational phase). When no phase-related acceleration or decelera-
tion was found, the breath was assigned a pvRSA score of zero. Automatic
scoring of RR and pvRSA was checked by visual inspection of the respiratory
signal and IBI time series from the entire recording. Breathing cycles that
showed irregularities like gasps, breath holding, coughing or that had IBI
artifacts (ectopic beats or too long beats due to failed R-wave detection) were
not considered valid and were rejected and removed from further processing.
In the remaining data, the shortest and longest breaths as well as the breaths
containing the shortest and longest IBIs (defined by 3 SD from the mean in
either direction) were automatically removed from the entire recording before
averaging pvRSA across all remaining breaths to a single mean pvRSA for
each of the labeled periods. In total, 74 subjects were removed from the final
data set because 25% of their breaths were discarded during automated or
visual data cleaning (36,37). RSA can alternatively be assessed as the high-
frequency power of the IBI time series by Fourier or Wavelet-analysis (38)
but it has been shown that the time and frequency domain measures
essentially pick up the same between-subject variation and can be used
interchangeably (37,39). The advantage of pvRSA assessments is that they
additionally yield the RR.
Recording is unobtrusive and subjects, who maintain full freedom of
movement, tend to habituate very rapidly to this type of recording. NESDA
subjects were wearing the VU-AMS device during a large part of the NESDA
clinic visit, at the same time participating in the different assessment parts.
The start of the various assessment stages was marked with an event marker
to divide the total recording into fixed periods (resting baseline, breaks,
interview 1, computer task, interview 2). Movement registration through
vertical accelerometry was used to excise periods where subjects were non-
stationary. Removal of breaks and nonstationary parts (about 15 minutes)
resulted in the four conditions used in the final analyses: a supine rest
condition with three blood pressure measurements (9.7  3.0 minutes), and
three conditions with mild cognitive load in which the subjects were sitting
upright: interview session 1 (investigating somatic health; functioning and
healthcare utilization; sitting, 38.2  12.7 minutes); interview session 2 (inves-
tigating family and personal history and life events; sitting, 35.6 12.7 minutes);
and a computer task (Implicit Association Task; sitting, 16.2  4.0 minutes).
The Implicit Association Task is a computerized task designed to measure
implicit associations between self items, on the one hand, and anxiety-related
and depression-related items, on the other hand (40).
Covariates
RR has often been associated with HRV and several studies suggested that
research investigating HRV should take RR into account (34,41). Therefore,
we adjusted analyses for RR. Sociodemographics included age, sex, and
education in years. In addition, various health indicators were considered as
covariates because these have been linked with both anxiety and ANS
activity. Body mass index (BMI) was determined as measured weight in
kilograms divided by the square of the measured height in meters. Physical
activity was measured using the International Physical Activity Questionnaire
(42) and expressed in MET-minutes per week (the multiple of one’s resting
metabolic rate times minutes of physical activity per week). Smoking status
was defined as a dichotomous variable; nonsmoker versus smokers. Three
categories were created for alcohol use: nondrinker, mild-to-moderate drinker
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(14 glasses a week), and heavy drinker (14 glasses a week). Self-reports
were used for ascertainment of the presence of heart disease (including
coronary disease, cardiac arrhythmia, angina, heart failure, and myocardial
infarction) and other chronic conditions (epilepsy, diabetes, osteoarthritis,
stroke, cancer, chronic lung disease, thyroid disease, liver disease, chronic fatigue
syndrome, intestinal disorders, and ulcer). Furthermore, it was determined
whether subjects were using heart medication by copying the names of medi-
cines from the containers brought in by the subjects. We classified medication
using the WHO Anatomical Therapeutic Chemical (ATC) classification (43).
First, a dichotomous variable for the use of  blockers was computed, scoring
“yes” if subjects frequently (daily or 50% of the time) used a medication
with ATC code starting with: C07 ( blocking agents). A second variable was
made for the use of other heart medication using ATC codes starting with:
C01 (cardiac therapy), C02 (antihypertensives), C03 (diuretics), C04 (periph-
eral vasodilators), C05 (vasoprotectives), or C08 (calcium-channel blockers).
In addition, we conducted additional analyses with covariates that may
further explain a potential association between anxiety and HR and HRV
function. First, because we recently found that antidepressants had a major
lowering impact on SDNN and RSA in depressed patients (28), frequent use
(daily or 50% of the time) of antidepressant medication was considered as
covariate. We distinguished selective serotonin reuptake inhibitors (SSRIs)
(ATC code N06AB), tricyclic antidepressants (TCAs) (ATC code N06AA),
and other antidepressants (including monoamine oxidase inhibitors, nonse-
lective N06AF, and antidepressants classified as N06AX). Second, we ex-
plored whether the association between anxiety disorder and HR and HRV
was explained by the presence of comorbid remitted or current major depres-
sive disorder (MDD) as assessed using the CIDI psychiatric interview. Third,
the importance of two indicators of severity of anxiety (BAI score and number
of anxiety disorders present) in the association with HR and HRV was
examined.
Statistical Analyses
Data were analyzed using SPSS 15.0. Characteristics across the three
anxiety groups (controls, remitted, and current anxiety) were compared using
analysis of variance (ANOVA) and 2 statistics. Mixed model analysis
showed that differences in ANS measures between anxiety groups were
similar for the computer task and interview parts and data during the computer
task and interview parts were collapsed to create a single “test” condition to
simplify analyses. ANOVAs were conducted separately for the rest and test
conditions to compare HR, SDNN, and RSA between the anxiety groups.
These analyses were repeated with consideration of covariates (RR, age, sex,
education, BMI, smoking, alcohol use, physical activity, heart disease, heart
medication, and chronic disease count). Subsequently, the role of two main
explanatory variables (antidepressant medication and comorbid major depres-
sive disorder) was examined by entering information on these variables in the
analyses of covariance.
TABLE 1. Main Sample Characteristics for Controls and Anxious Subjects
Variablea
Control Remitted Anxiety Current Anxiety
pa
(n  616) (n  421) (n  1159)
Age, years (mean  SD) 41.1  14.7 43.6  12.6 40.9  12.3 .001
Sex, % (female) 61 70.5 68.1 .002
Education, years (mean  SD) 12.8  3.2 12.5  3.1 11.6  3.3 .001
BMI (mean  SD) 25.1  4.6 25.7  5.0 25.6  5.2 .06
Physical activity, 1000 MET min/week (mean  SD) 3.8  3.1 3.6  2.8 3.6  3.1 .28
Smoking (% yes) 25.9 32.3 46.6 .001
Alcohol use (%)
Nondrinker 11 15.2 22 .001
Mild/moderate drinker 71.2 69.8 62.6
Heavy drinker 17.8 15 15.4
 ( %) 	
 	 6.5 9 8 .29
Other heart or blood pressure
medication (% yes) 11.7 11.2 9.7 .4
Heart or coronary disease (% yes) 4.7 5.5 6.3 .38
Chronic diseases (mean nr.  SD) 1.01  1.1 1.30  1.2 1.37  1.3 .001
Medication use
Tricyclic antidepressants (% yes) 0 2.9 4.2 .001
Selective serotonin reuptake inhibitors (% yes) 0 15.9 27.1 .001
Other antidepressants (% yes) 0 3.8 9.5 .001
Comorbid major depressive disorder 0 75.3 79.4 .001
Panic disorderb
Remitted (% yes) 0 35.2 4.4 .001
Current (% yes) 0 0 55.4
Social phobiab
Remitted (% yes) 0 41.1 5.1 .001
Current (% yes) 0 0 55.5
Generalized anxiety disorderb
Remitted (% yes) 0 48.7 8.8 .001
Current (% yes) 0 0 38.2
Respiratory rate,c breaths per minute (mean  SD) 17.2  1.2 17.0  1.1 17.1  1.2 .02
BAI score (mean  SD) 4.0  4.8 9.2  7.6 18.9  10.9 .001
a Comparison using analysis of variance analyses (continuous variables) and 2 statistics (categorical variable).
b Percentages anxiety disorders do not add up due to comorbidity.
c Respiratory rate is averaged over rest and test conditions.
SD  standard deviation; MET  multiple of the resting metabolic rate; BAI  Beck Anxiety Inventory.
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To examine whether different anxiety disorders had differential associa-
tions with HR and HRV, we conducted multivariate regression analyses on
HR, SDNN, and RSA including covariates and anxiety subtype indicators.
Finally, we distinguished anxious with and without various types of psycho-
active medication and compared their HR, SDNN, and RSA with those of
controls in fully corrected analyses of covariance (ANCOVAs). Effect sizes
were calculated with Cohen’s d (1988) defined as the difference in the mean
RSA, SDNN, and HR between two groups, divided by the pooled standard
deviation (SD) of these groups.
RESULTS
The mean  SD age of the study sample (n  2195) was
41.7  13.1 years, 66.8% was female, and 50.9% had 12
years of education. Table 1 shows the demographic charac-
teristics, disease status, lifestyle habits, and medication use
according to anxiety diagnosis. Of the individuals with a
current anxiety disorder, 55.4% had a PD, 55.5% had a social
phobia, and 38.2% had a generalized anxiety disorder. Com-
pared with the nonanxious subjects, anxious subjects were
more likely to be female, had less education, had a higher
BMI, were more likely to smoke but less likely to drink, had
more chronic diseases, were more likely to use antidepres-
sants, had a lower RR, and had a higher BAI score.
Table 2 presents the results of the unadjusted and adjusted
ANOVA analyses on HR, SDNN, RSA for anxiety status for
the rest and test conditions. Results showed that HR did not
differ in either condition between current or remitted anxious
subjects and healthy controls, independent of covariates. For
TABLE 2. Heart Rate (bmp), SDNN (ms), and RSA (ms) in Control and Anxiety Disorders, Raw and Adjusted for Covariates
Control
(n  616)
Remitted Anxiety
Disorder
(n  420)
Control Versus
Remitted Anxiety
Disorder
Effect Sizes
Control Versus
Remitted
Anxiety
Current Anxiety
Disorder
(n  1159)
Control Versus
Current Anxiety
Disorder
Effect Size
Control Versus
Current Anxiety
Rest condition
Heart rate (mean  SE)
Unadjusted 68.4  0.4 68.8  0.5 0.61 0.032 69.3  0.3 0.05 0.096
Basic adjustmenta 68.5  0.4 68.8  0.5 0.65 0.029 69.1  0.3 0.22 0.062
Full adjustmentb 68.7  0.4 68.8  0.5 0.84 0.013 69.0  0.3 0.51 0.033
Adjustment for
antidepressant use
69.0  0.4 69.0  0.5 0.95 0.004 68.8  0.3 0.75 0.017
SDNN (mean  SE)
Unadjusted 79.1  1.3 74.3  1.6 0.02 0.146 72.9  1.0 0.001 0.189
Basic adjustmenta 78.5  1.2 76.3  1.5 0.26 0.071 72.5  0.9 0.001 0.199
Full adjustmentb 77.7  1.2 76.3  1.5 0.46 0.047 73.0  0.9 0.002 0.156
Adjustment for
antidepressant use
75.6  1.3 75.7  1.4 0.94 0.005 74.2  0.9 0.40 0.044
RSA (mean  SE)
Unadjusted 51.3  1.3 45.0  1.5 0.002 0.200 45.4  0.9 0.001 0.188
Basic adjustmenta 51.6  1.1 46.9  1.3 0.005 0.182 44.5  0.8 0.001 0.273
Full adjustmentb 51.4  1.1 47.0  1.3 0.009 0.165 44.7  0.8 0.001 0.250
Adjustment for
antidepressant use
48.5  1.1 46.4  1.3 0.21 0.079 46.3  0.8 0.12 0.082
Test condition
Heart rate (mean  se)
Unadjusted 73.4  0.4 72.6  0.5 0.20 0.083 73.1  0.3 0.46 0.037
Basic adjustmenta 73.5  0.4 72.9  0.5 0.31 0.064 73.0  0.3 0.30 0.052
Full adjustmentb 73.5  0.4 72.9  0.5 0.32 0.062 72.9  0.3 0.24 0.060
Adjustment for
antidepressant use
73.6  0.4 73.0  0.5 0.33 0.061 72.9  0.3 0.13 0.079
SDNN (mean  SE)
Unadjusted 65.6  0.9 63.9  1.1 0.23 0.077 62.8  0.7 0.02 0.123
Basic adjustmenta 65.4  0.9 65.1  1.0 0.86 0.011 62.5  0.6 0.007 0.138
Full adjustmentb 64.9  0.9 65.1  1.0 0.91 0.007 62.7  0.6 0.04 0.104
Adjustment for
antidepressant use
63.4  0.9 64.6  1.0 0.36 0.058 63.6  0.6 0.85 0.010
RSA (mean  SE)
Unadjusted 46.6  1.0 42.4  1.3 0.01 0.168 43.4  0.8 0.01 0.128
Basic adjustmenta 47.1  0.9 44.2  1.1 0.04 0.124 42.5  0.6 0.001 0.182
Full adjustmentb 47.1  0.9 44.2  1.1 0.03 0.120 42.5  0.7 0.001 0.175
Adjustment for
antidepressant use
45.1  0.9 43.6  1.0 0.31 0.074 43.7  0.7 0.25 0.062
a Adjusted for respiratory rate, age, sex, and education.
b Additionally adjusted for body mass index, physical activity, smoking, alcohol use, chronic disease,  blocking agents, other heart medication, and heart disease.
SDNN  root mean square of successive differences; RSA  respiratory sinus arrhythmia; SE  standard error.
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TABLE 3. Results of Regression Analyses Predicting Heart Rate (bpm), SDNN (ms), and RSA (ms) Among Controls and Anxious Subjects
Heart Rate SDNN RSA
B p R2 B p R2 B p R2
Rest condition
Model 1 .097 .205 .324
Respiratory rate (per 1 breath per minute
increase)
0.452 .001 1.745 .001 3.063 .001
Age (per 1 year increase) 0.040 .03 0.988 .001 1.319 .001
Sex (female versus male) 2.498 .001 6.111 .001 7.706 .001
Education (per 1 year increase) 0.068 .29 0.180 .38 0.276 .13
Physical activity (per 1000 MET-minutes a
week increase)
0.171 .07 0.370 .07 0.159 .39
BMI (per 1 kg/m2 increase) 0.285 .001 0.574 .001 0.405 .001
Heavy alcohol use versus no alcohol use 1.735 .02 5.971 .009 5.690 .005
Mild/moderate alcohol use versus no
alcohol use
1.799 .001 7.279 .001 4.904 .002
Smoking (yes versus no) 1.107 .01 1.435 .30 0.377 .76
Chronic disease (per 1 disease increase) 0.139 .42 0.067 .90 0.576 .24
Heart disease (yes versus no) 0.654 .49 2.120 .49 1.936 .47
-blocking agents (yes versus no) 7.341 .001 0.874 .75 2.318 .34
Other heart medication (yes versus no) 2.257 .003 2.095 .39 0.468 .83
Current panic disorder (yes versus no) 0.226 .64 2.639 .08 3.066 .02
Remitted panic disorder (yes versus no) 0.306 .67 4.004 .08 4.053 .05
Current social phobia (yes versus no) 0.349 .45 3.071 .04 4.471 .001
Remitted social phobia (yes versus no) 0.256 .71 1.352 .53 2.786 .14
Current generalized anxiety disorder (yes
versus no)
.0.079 .88 3.648 .03 2.242 .13
Remitted generalized anxiety disorder (yes
versus no)
0.148 .80 0.660 .73 0.542 .75
Model 2 (Model 1  antidepressant use)a .118 .222 .349
Current panic disorder (yes versus no) 0.412 .40 0.804 .60 0.234 .86
Remitted panic disorder (yes versus no) 0.209 .77 2.632 .25 1.915 .34
Current social phobia(yes versus no) 0.138 .77 1.882 .20 0.2.777 .03
Remitted Social Phobia (yes versus no) 0.359 .59 2.246 .30 1.245 .51
Current generalized anxiety disorder (yes
versus no)
0.130 .81 1.837 .27 0.122 .93
Remitted generalized anxiety disorder (yes
versus no)
0.257 .59 1.513 .42 0.669 .68
Use of a tricyclic antidepressant (yes
versus no)
7.811 .001 15.340 .001 15.334 .001
Use of a selective serotonin reuptake
inhibitor (yes versus no)
0.182 .75 5.191 .004 10.500 .001
Use of an other antidepressant
(yes versus no)
3.054 .001 15.263 .001 14.284 .001
Test condition
Model 1 .123 .191 .313
Respiratory rate (per 1 breath per minute
increase)
1.098 .001 2.750 .001 3.770 .001
Age (per 1 year increase) 0.085 .001 0.647 .001 1.045 .001
Sex (female versus male) 2.306 .001 3.575 .001 6.906 .001
Education (per 1 year increase) 0.059 .36 0.117 .41 0.038 .80
Physical activity (per 1000 MET-minutes a
week increase)
0.185 .005 0.272 .06 0.098 .52
BMI (per 1 kg/m2 increase) 0.179 .001 0.397 .001 0.174 .09
No alcohol use versus heavy alcohol use 0.926 .20 2.611 .10 2.242 .19
No alcohol use versus mild/moderate
alcohol use
1.271 .02 3.022 .01 2.991 .02
Smoking (yes versus no) 0.111 .80 1.399 .15 1.410 .16
Chronic disease (per 1 disease increase) 0.040 .82 0.103 .79 0.366 .37
Heart disease (yes versus no) 0.562 .56 0.821 .71 0.663 .77
-blocking agents (yes versus no) 9.180 .001 2.526 .19 2.123 .30
Other heart medication (yes versus no) 2.207 .004 2.745 .11 0.797 .66
Current panic disorder (yes versus no) 0.784 .10 0.968 .36 2.345 .04
(Continued)
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SDNN, a significant difference was found between the current
anxious subjects and the controls in both conditions (in the
adjusted model, .002  p  .04 and .104  Cohen’s d 
0.156) and for RSA, significant differences were found be-
tween the controls and both the current and the remitted
anxious subjects for both the rest (p  .001, Cohens d 
0.175–0.250) and test (.009  p  .03, Cohen’s d  0.120–
0.165) conditions in the fully adjusted model. Additional
correction for the BAI score did not change results. Table 2
shows that, in case of SDNN as well as RSA, correction for
antidepressant use reduced the differences between the anxi-
ety groups and the control group to nonsignificant.
Table 3 presents the results of the nominal linear regression
analyses using the separate anxiety disorders as independent
predictors of HR, SDNN, and RSA. Model 1 includes all
possible predictors and Model 2 additionally includes the use
of different antidepressants. HR was not significantly different
from controls in the rest or test condition in any of the three
anxiety disorders. However, current anxiety disorders were
associated with significantly lower SDNN and RSA, and RSA
was also significantly lower in subjects with remitted anxiety
disorders. Model 2 shows that all these associations became
nonsignificant after adding TCA, SSRI, and other antidepres-
sant use to the model. The use of especially a TCA had a
major effect on both SDNN (for the rest and test conditions,
B  15.340 and B  16.159, p  .001), and RSA (B 
14.943 and B  15.334, p  .001). The use of an SSRI or
other antidepressant also showed this effect, although with a
more modest effect size (B values range  3.638 to
15.263; p values range .004 to.001). Significant effects
of antidepressant use were also found for HR; the use of a
TCA or other antidepressant increased HR (for the rest and
test conditions, respectively, B  7.811 to B  8.101, p 
.001; and B  1.975 to B  3.054, p  .02–0.001). Addi-
tional correction for comorbid depression did not change these
effects as comorbid depression itself was not significantly
associated with SDNN and RSA. Repeating the regression
analyses in Table 3 with RSA divided by the IBI (as suggested
by Grossman and Kollai) (44) yielded essentially identical
results.
Because the regression analyses (Table 3) showed strong
effects of antidepressants on the cardiac measures, we decided
to analyze further the differences in HR, SDNN, and RSA
between controls, anxious subject without medication and
anxious subject on TCAs, SSRIs, and other antidepressants.
Eventually, five groups of anxiety subjects were distin-
guished: 326 remitted anxious subjects without medication;
701 current anxious subjects without medication; 60 anxious
subjects on a TCA; 376 anxious subjects on a SSRI (no TCA
users); and 116 anxious subjects on other antidepressants (no
TCA or SSRI users). ANCOVAs were performed to compare
these groups with each other on mean HR, SDNN, and RSA.
Table 4 provides the main characteristics of the anxious sub-
jects with and without medication. Medicated anxious indi-
TABLE 3. Continued
Heart Rate SDNN RSA
B p R2 B p R2 B p R2
Remitted panic disorder (yes versus no) 0.083 .91 0.865 .59 2.400 .15
Current social phobia (yes versus no) 0.094 .84 1.092 .29 2.222 .04
Remitted social phobia (yes versus no) 0.061 .93 1.767 .24 3.158 .05
Current generalized anxiety disorder (yes
versus no)
0.233 .65 3.177 .007 3.516 .004
Remitted generalized anxiety disorder (yes
versus no)
1.020 .08 1.573 .23 0.833 .55
Model 2 (Model 1  antidepressant use)a .145 .213 .333
Current panic disorder (yes versus no) 0.732 .13 0.261 .81 0.433 .70
Remitted panic disorder (yes versus no) 0.003 .99 0.059 .97 0.970 .56
Current social phobia (yes versus no) 0.005 .99 0.186 .86 1.003 .36
Remitted social phobia (yes versus no) 0.068 .92 1.106 .46 2.092 .18
Current generalized anxiety disorder (yes
versus no)
0.217 .68 1.995 .09 1.906 .12
Remitted Generalized anxiety disorder (yes
versus no)
1.038 .08 2.192 .09 0.028 .98
Use of a tricyclic antidepressant (yes
versus no)
8.101 .001 16.159 .001 14.943 .001
Use of a selective serotonin reuptake
inhibitor (yes versus no)
1.163 .04 3.638 .004 6.937 .001
Use of another antidepressant (yes
versus no)
1.975 .02 9.286 .001 9.873 .001
a Model 2 included all covariates of Model 1 as well as antidepressant use variables. Regression coefficients are only shown for anxiety and antidepressant use
variables.
MET multiple of the resting metabolic rate; RSA respiratory sinus arrhythmia; SDNN root mean square of successive differences; bpm, beats per minute;
ms  milliseconds; BMI  body mass index.
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viduals were older, had a higher mean BMI, performed less
physical activity, drank less, more often used  blocking
agents and other heart or blood pressure medication, had more
comorbid MDD and remitted anxiety disorder diagnoses, and
had a higher mean BAI score.
Although remitted and current anxious patients without
antidepressant medication also differed significantly in BAI
score (8.5 and 17.5, respectively), they both did not differ
significantly from the controls in terms of HR, SDNN, or RSA
in rest or test conditions adjusted for covariates (Table 5;
Figure 1). Addition of the BAI score as a covariate did not
change this outcome. In contrast, all anxiety patients on an
antidepressant, with BAI scores similar to the current anxious
patients without medication, had a significantly lower SDNN
and RSA compared with the controls in both conditions (all
p  .003 for SDNN and RSA), with effect sizes ranging
between d 0.197 and d 0.799 with the highest effect sizes
for TCA users. The antidepressants had parallel effects on HR,
with the exception of SSRIs. Anxious TCA users had a sig-
nificantly higher HR compared with controls with a large
effect size (d  0.802–0.827). Smaller HR increases were
found in anxious users of other antidepressants (p  .09–
0.001 and d  0.172–0.339). In anxious SSRI users, the
opposite effect was found such that HR was lower than in
anxious subjects without medication, although only in the test
condition (p  .005 and d  0.185).
DISCUSSION
This large-scale cohort study showed that, when compared
with healthy controls, subjects with an anxiety disorder have
a significantly lower total HRV, an established risk factor for
CVD (11,15,45), and significantly lower RSA, which is con-
TABLE 4. Main Sample Characteristics for Anxious Subjects Taking and Not Taking Antidepressants
Current Anxiety No
Medication
Anxiety on
TCA
Anxiety on
SSRI
Anxiety on Other
Antidepressants pa
(n  701) (n  61) (n  380) (n  118)
Age, years (mean  SD) 40.2  12.8 47.2  10.4 41.4  11.6 43.2  10.9 .001
Sex, % (female) 69.5 73.8 69.7 60.2 .16
Education, years (mean  SD) 11.7  3.3 11.2  3.5 11.7  3.3 11.7  3.2 .73
BMI (mean  SD) 25.2  4.9 27.4  6.2 26.3  5.7 25.9  5.5 .001
Physical activity, 1000 MET
min/week (mean  SD)
3.8  3.2 2.8  2.5 3.5  3.2 3.1  3.1 .03
Smoking, % yes 43.7 52.5 45.5 52.5 .22
Alcohol use, %
Nondrinker 18.3 37.7 25.8 26.3 .001
Mild/moderate drinker 64.9 49.2 59.5 65.3
Heavy drinker 16.8 13.1 14.7 8.5
-blocking agents (%yes) 7.2 14.8 7.4 12.7 .05
Other heart or blood pressure
medication, % yes
8.3 21.3 8.9 15.3 .002
Heart or coronary disease, %
yes
5.4 6.6 6.6 5.1 .86
Chronic diseases (mean nr. 
SD)
1.35  1.2 1.64  1.6 1.33  1.3 1.47  1.4 .28
Medication use
TCAs, % yes 0 100 0 0 .001
SSRIs, % yes 0 6.6 100 0 .001
Other antidepressants, %
yes
0 3.3 2.1 100 .001
Comorbid major depressive
disorder
72.6 88.5 89.7 91.5 .001
Panic disorderb
Remitted, % yes 4.2 9.8 13.7 11 .001
Current, % yes 50.7 42.6 53.4 51.7 .45
Social phobiab
Remitted, % yes 4.2 13.1 14.5 7.6 .001
Current, % yes 56 47.5 45.5 44.9 .004
Generalized anxiety disorderb
Remitted, % yes 8.9 16.4 15.3 14.4 .007
Current, % yes 35.4 24.6 33.7 44.9 .04
BAI score (mean  SD) 17.6  10.7 20.0  12.4 19.4  11.4 19.7  10.4 .02
a Comparison using analysis of variance (ANOVA) (continuous variables) and 2 statistics (categorical variable).
b Percentages anxiety disorders do not add up due to comorbidity.
TCAs  tricyclic antidepressants; SSRIs  selective serotonin reuptake inhibitors; SD  standard deviation; BMI  body mass index; MET  multiple of the
resting metabolic rate; BAI  Beck Anxiety Inventory; nr  number.
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sidered to reflect the lower cardiac vagal control (46,47) that
might underlie this increased risk (48). The lower HRV was
not specific to PD, but was found for all anxious individuals,
whether afflicted with PD, SP, or GAD. Lower HRV, espe-
cially lower cardiac vagal control, was not only observed
among current anxiety patients but also among those with a
remitted diagnosis. In all instances, the effect sizes were very
modest, with d values between 0.10 and 0.25. Very similar
results were found in the supine rest condition and the (much
longer) active test condition.
A major aim of the study was to examine the extent to
which the potential association between the presence of anx-
iety disorders and HRV is confounded by lifestyle and use of
antidepressants, and this may have been the first study suffi-
ciently powered to do so. Compared with all previous studies,
we used a large sample of patients with remitted or current
anxiety, both medicated and nonmedicated, who were ascer-
tained in multiple ways to obtain a representative population
sample of patients. In addition, the availability of prolonged
ambulatory recordings of SDNN and RSA in the nearly com-
plete sample provided us with stable and reliable indicators.
Our findings showed that lower HRV in anxious subjects
survived adjustment for possible confounding factors as health
indicators and lifestyle, but further adjustment for antidepres-
sant use rendered all associations nonsignificant.
Considering the effects of age on the cardiac indices, our
result are in line with other studies reporting significant de-
creases in HR and HRV with age (49–52). In our study,
females had a significantly higher HR and RSA, but lower
SDNN compared with males, which is in accordance with
earlier findings (50–52). Although several papers have been
published on HRV and obesity, few studies have addressed the
relationship between HRV and continuous BMI, and findings
have been inconsistent (50,53–55). In line with Kageyama
et al. (55) and Britton et al. (53), we found that an increase in
BMI was significantly associated with an increase in HR and
a decrease in SDNN, but the effect of BMI on RSA was not
significant. We found no significant effect of smoking on HR
and HRV, which concurs with some (55) but contrasts with
other previous reports (56). In contrast to many smaller studies
TABLE 5. Heart Rate (bpm), RSA (ms) and SDNN (ms) per Medication Groupa
n BAI Score
Heart Rate SDNN RSA
Mean  SE p Effect Size Mean  SE p Effect Size Mean  SE p Effect Size
Rest condition
Control 616 4 68.7  0.4 REFb REFb 77.9  1.2 REFb REFb 51.6  1.1 REFb REFb
Any remitted anxiety
disorder, no
medication
326 8.5 68.7  0.5 .95 0.005 77.7  1.6 .91 0.008 49.5  1.4 .24 0.08
Any current anxiety
disorder, no
medication
701 17.5 68.3  0.4 .54 0.035 77.0  1.1 .59 0.031 49.7  1.0 .19 0.074
Any anxiety disorder
on TCA
60 19.9 76.4  1.2 .001 0.827 60.5  3.8 .001 0.59 32.9  3.3 .001 0.719
Any anxiety disorder
on SSRI
376 19.1 68.5  0.5 .74 0.022 70.6  1.5 .001 0.246 38.5  1.3 .001 0.505
Any anxiety disorder
on other
antidepressant
116 19.9 71.8  0.9 .001 0.339 60.3  2.7 .001 0.596 33.9  2.4 .001 0.68
Test condition
Control 616 4 73.5  0.4 REFb REFb 65.1  0.8 REFb REFb 47.6  0.9 REFb REFb
Any remitted anxiety
disorder, no
medication
326 8.5 73.1  0.5 .58 0.038 65.8  1.1 .62 0.034 45.6  1.2 .18 0.091
Any current anxiety
disorder, no
medication
701 17.5 72.5  0.3 .07 0.103 65.8  0.8 .56 0.033 46.7  0.8 .43 0.045
Any anxiety disorder
on TCA
60 19.9 80.9  1.2 .001 0.802 48.6  2.7 .001 0.799 30.4  2.8 .001 0.79
Any anxiety disorder
on SSRI
376 19.1 71.7  0.5 .005 0.185 61.0  1.1 .003 0.197 38.5  1.1 .001 0.417
Any anxiety disorder
on other
antidepressant
116 19.9 75.1  0.9 .09 0.172 55.6  1.9 .001 0.463 34.8  2.0 .001 0.586
a Adjusted for respiratory rate, age, sex and education, body mass index, physical activity, smoking, alcohol use, heart disease, chronic disease, and heart
medication.
b Control is the reference group. All p values and effect sizes are for comparison of the group in that specific line and control subjects.
RSA respiratory sinus arrhythmia; SDNN root mean square of successive differences; TCA tricyclic antidepressant; SSRI selective serotonin reuptake
inhibitor; AD  antidepressant.
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reporting no effect or a detrimental effect of acute or chronic
alcohol use on ANS functioning (55,57–61), we found that
moderate and mild drinkers had a significantly higher HRV
and lower HR compared with nondrinking individuals. Our
results show that physically active subjects have a lower HR
and higher SDNN, as observed previously (14,62,63). RSA,
however, was not significantly higher in the more active
individuals.
Although these lifestyle factors may act as potential con-
founders, multivariate analyses showed that they did not ex-
plain the lower SDNN and RSA in patients with anxiety
disorders. Instead, this association seemed to be mainly driven
by the effects of antidepressants. Anxious subjects receiving
antidepressants showed significantly lower RSA (effect sizes
between d  0.415 and d  0.783) and SDNN (effect sizes
between d 0.195 and d 0.792), whereas differences between
controls and anxious subjects without antidepressants were
nonsignificant independent of present or past diagnosis. This
effect was also independent of anxiety severity because cur-
rent anxious subjects without and with medication hardly
differed in BAI severity score, whereas they significantly
differed in terms of HR, SDNN, and RSA. Also, additional
correction for anxiety severity and comorbid MDD did not
change the results. Although the effects of TCAs, which have
previously been reported to have a powerful tachycardiac
effect (64–66), were the most prominent (effect sizes  around
0.8), the antidepressant effects were not limited to TCAs. Con-
sistently lower SDNN and RSA were also found in anxious
patients using SSRIs (effect sizes  between 0.2 and 0.4) and
other antidepressants (effect sizes  between 0.5 and 0.6).
The above results and conclusions must be weighed by
some limitations of this study. First, this study was performed
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Figure 1. Heart rate (bpm), SDNN (ms) and RSA (ms) in controls, anxious subjects without medication and anxious subjects on medication. * .05  p  .10;
** p .005; all p values compare anxious subjects with controls. HR heart rate; TCA tricyclic antidepressant; SSRI selective serotonin reuptake inhibitor;
AD  antidepressant; SDNN  standard deviation of the normal-to-normal intervals; RSA  respiratory sinus arrhythmia.
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during a clinic visit involving uncommon procedures, unfa-
miliar research assistants, and interviews with questions of a
personal nature. Anxious patients may be more inclined to
respond to such challenges with decreased cardiac vagal tone,
and our results may have partially reflected this. It is unclear,
however, how this “laboratory anxiety” can account for the
observed effects of antidepressant medication on RSA and
SDNN. Nonetheless, generalizability to a more familiar and
less stressful real life setting cannot be assumed without actual
ambulatory recording. Second, the demands of the already
vulnerable participants of this large longitudinal cohort study
did not allow us to add a true stress condition to the design.
The test condition was not intended to be stressful and the
mild decrease in HRV levels compared with supine rest
should be attributed mainly to the change in posture. There-
fore, we could not test the idea that ANS reactivity to stressors
differs between anxious subjects and healthy controls as is
implied by theoretical models like the polyvagal theory and
the autonomic flexibility-neurovisceral integration model
(67,68). Finally, we cannot exclude systematic differences in
cardiac sympathetic control or intrinsic HR between the var-
ious groups in this study, which may have affected our mea-
sures of HRV and cardiac vagal control. Medication-specific
effects on sympathetic nervous system activity, for instance,
might explain why we find lower HRV in anxious subjects
using SSRIs but not higher HR. To resolve this, additional
measures of cardiac sympathetic control would have been
needed.
In sum, our findings demonstrate that subjects with an
anxiety disorder have a lower SDNN and RSA. The major part
of this association was due to the effect of antidepressant use
because the use of TCAs and SSRIs as well as other antide-
pressants had a pronounced effect on HRV. As it has been
widely established that lowered HRV is a risk factor for
cardiovascular morbidity and mortality (11,15,45,48), our
findings of lower SDNN and RSA in antidepressant users
could be of importance for clinical practice. However, cause and
effect remain to be established. Before longitudinal follow-up
data are available, we do not know whether the lower SDNN and
RSA are caused by antidepressants and whether the low
SDNN and RSA found in medicated subjects is reversed when
subjects cease their medication. It is also an open question
whether lower HRV found in antidepressant users is out-
weighed by the beneficial effects of antidepressant medication
on anxiety and future heart disease.
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